SCHEMBL319270

SCHEMBL319270

NC(=O)c1ncccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
HTT P42858 1/20 0.49
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
BLM P54132 1/20 0.44
AGER Q15109 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 1/20 0.43
PARP1 P09874 1/20 0.43
NAPRT Q6XQN6 2/20 0.42
MKNK1 Q9BUB5 2/20 0.42
MKNK2 Q9HBH9 2/20 0.42
CTNNB1 P35222 1/20 0.41
WNT3A P56704 1/20 0.41
CTSA P10619 2/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18694922 0.98 MAPT (0.47) MAPTHTTKDM4EALDH1A1CYP3A4
SCHEMBL17506235 0.83 MAPT (0.43) MAPTHTTKDM4EALDH1A1CYP3A4
SCHEMBL5285579 0.83 MAPT (0.47) MAPTHTTKDM4EALDH1A1PARP1
SCHEMBL17136101 0.82 MKNK1 (0.43) MAPTHTTKDM4EALDH1A1CYP3A4
SCHEMBL1315947 0.81 MAPT (0.39) MAPTHTTKDM4EALDH1A1CYP3A4
SCHEMBL20054565 0.81 KDM4E (0.45) MAPTHTTKDM4EALDH1A1CYP3A4
SCHEMBL287811 0.81 KDM4E (0.61) MAPTKDM4EALDH1A1CYP3A4ALOX15
SCHEMBL13886916 0.79 MAPT (0.38) MAPTHTTKDM4EALDH1A1CYP3A4
SCHEMBL1874614 0.79 KDM4E (0.59) MAPTKDM4EALDH1A1CYP3A4ALOX15
SCHEMBL1812108 0.79 ALDH1A1 (0.45) MAPTHTTKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069605-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-03-12 US claimed
CN-119410714-A Tracer for in-vivo visualization of synapse formation and construction method thereof 浙江大学 2025-02-11 CN claimed
EP-4069691-B1 SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-09-18 EP claimed
US-11999699-B2 Substituted pyrazole amides Grünenthal GmbH (DE) 2024-06-04 US claimed
CN-117586963-A Reporter gene modified stem cell, preparation method thereof and brain tracing application 浙江大学 2024-02-23 CN claimed
EP-3833438-B1 SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-02-07 EP claimed
EP-3600312-B1 PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 TAKEDA PHARMACEUTICALS CO (JP) 2023-05-17 EP claimed
EP-3743406-B9 TMEM16A MODULATORS TMEM16A LTD (GB) 2023-03-08 EP claimed
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES GRUENENTHAL GMBH (DE) 2023-01-26 US claimed
EP-3743406-B1 TMEM16A MODULATORS TMEM16A LTD (GB) 2022-12-28 EP claimed
CN-105254624-B Isothizole derivatives PIM kinase inhibitor and preparation method thereof and the application in pharmacy 上海吉铠医药科技有限公司 2019-08-09 CN claimed
CN-105130959-B Pyrimidine derivatives PIM kinase inhibitors and preparation method thereof and the application in pharmacy 上海吉铠医药科技有限公司 2018-08-03 CN claimed
US-20260125382-A1 COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-05-07 US disclosed
US-20260069605-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-03-12 US disclosed
US-12442289-B2 Oil, gas and water well tracers with tunable release profile SAUDI ARABIAN OIL COMPANY (SA) 2025-10-14 US disclosed
EP-4611899-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE Petra Pharma Corporation (US) 2025-09-10 EP disclosed
CN-101343366-B Nano-laminal compound with regular array of pyridine and its derivant, and preparation thereof UNIV SHANGHAI 2011-05-04 CN disclosed
WO-2011050316-A1 MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY (US) 2011-04-28 WO disclosed
WO-2011029104-A1 MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY (US) 2011-03-10 WO disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999699-B2 Substituted pyrazole amides SCN8A, SCN1A, SCN7A MAPT 2901/4885HTT 3752/4885KDM4E 2803/4885
US-20260125382-A1 COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF CDK9, CDK20, CDK19 MAPT 4335/4885HTT 2020/4885KDM4E 1181/4885
US-20260069605-A1 KRAS INHIBITORS KRAS, NRAS, HRAS MAPT 4823/4885HTT 2787/4885KDM4E 4653/4885
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES SCN8A, SCN1A, SCN7A MAPT 2901/4885HTT 3752/4885KDM4E 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.